Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2018 07:00 ET | Source: Kura Oncology, Inc.

OncoDNA announces screening collaboration with Kura Oncology

- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib- Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium, May 22, 2018 (GLOBE...
May 08, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update

– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in second half of 2018 – – Data from multiple Phase 2 trials of...
May 03, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference

SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
May 02, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies

– Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 – – Second U.S. patent for tipifarnib reinforces potential for...
May 01, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report First Quarter 2018 Financial Results

SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
April 09, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018

SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
March 16, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at Oppenheimer 28th Annual Healthcare Conference

SAN DIEGO, March 16, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
March 12, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results

– Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 following recent end of Phase 2 meeting with the FDA – – Single-arm trial to enroll at least 59...
March 06, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference

SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
March 05, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results

SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...